Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Cognito's light-and-sound Alzheimer's headset fails pivotal trial
00

Cognito's light-and-sound Alzheimer's headset fails pivotal trial

Nov 17, 2026

Cognito Therapeutics announced that a 12-month clinical trial of its Spectris AD headset failed to slow cognitive decline in mild-to-moderate Alzheimer's disease patients overall, with device users declining by 8.97 points compared to 8.82 points in the sham group. However, subgroup data indicated up to 56 percent slower decline in mild cases, prompting CEO Christian Howell to plan a U.S. Food and Drug Administration submission by 2027. Independent experts caution that these exploratory subgroup findings require verification.

Spectris AD clinical trial failures

  • ▪In 2024, a smaller clinical trial of the Spectris AD device failed to slow cognitive and functional decline in people with Alzheimer's disease
  • ▪In a 12-month clinical trial of 673 participants with mild to moderate Alzheimer's disease, Cognito Therapeutics' Spectris AD device failed overall, with active users declining an average 8.97 points on a 156-point scale versus 8.82 points for sham users

Spectris AD trial design

  • ▪Trial instructions directed participants to wear the Spectris AD headset for 50 to 60 minutes a day, at least five days a week, over 12 months
  • ▪Approximately half of Cognito Therapeutics' 12-month clinical trial's participants were randomly assigned to use an active Spectris AD device, while the remainder received a sham placebo device

Spectris AD subgroup trial results

  • ▪Cognito Therapeutics trial data indicated the Spectris AD device slowed cognitive decline by 41.6 percent versus sham in mild Alzheimer's disease, and up to 56 percent across standardized measures in early symptomatic Alzheimer's
  • ▪In Cognito Therapeutics' 12-month clinical trial, the Spectris AD device slowed cognitive decline by 47 percent in people with early symptomatic Alzheimer's disease on a second functional measurement

Expert reactions to trial failure and subgroup claims

  • ▪Eric McDade, a neurologist at Washington University School of Medicine in St. Louis, characterized the Spectris AD trial as negative and stated any next step should be a follow-up study
  • ▪Rob Howard, a dementia psychiatrist at University College London, stated that the Spectris AD clinical trial failure would ordinarily prevent a treatment from seeking regulatory approval
  • ▪Heather Snyder, senior vice president at the Alzheimer's Association, stated that suggested benefits of the Spectris AD device in mild Alzheimer's disease remain unproven and require verification

Future regulatory plans and clinical role of Spectris AD

  • ▪Stephanie Buss, a cognitive neurologist at Beth Israel Deaconess Medical Center, stated that an approved Spectris AD device would complement rather than replace existing Alzheimer's drugs
  • ▪Cognito Therapeutics chief executive officer Christian Howell announced plans to petition the U.S. Food and Drug Administration for Spectris AD device approval in 2027

Mechanism and underlying research of gamma wave stimulation

  • ▪Cognito Therapeutics chief executive officer Christian Howell stated that stimulating the brain at 40 hertz preserves brain structure and function without clearing amyloid plaques or tau proteins
  • ▪Research led by MIT neuroscientists Li-Huei Tsai and Ed Boyden in 2016 demonstrated that light and sound stimulation triggered gamma brainwaves that cleared amyloid plaques in mice

2 sources

The Boston Globe
Device that uses light and sound may slow Alzheimer’s symptoms in some patients
View source article
Nature Medicine
‘Light and sound’ therapy for Alzheimer’s flops in long-anticipated trial
View source article

Story comments

Loading comments…

Related Projects

Alzheimer's Association

Topics

Neurodegenerative diseaseAlzheimer's diseaseAlzheimer’s & dementiaNeuroscienceFDA regulatory approvalDrug Policy, Pricing & ApprovalRandomized controlled trialClinical trials